MarketScreener Strategies Vertex Pharmaceuticals Incorporated
Stocks
VRTX
US92532F1003
Pharmaceuticals
|
Market Closed -
Nasdaq
16:00:00 2026-09-28 EDT
|
5-day change | 1st Jan Change | ||
| 527.67 USD | +0.28% |
|
+3.32% | +16.39% |
| 09-28 | UBS Raises Vertex Pharmaceuticals Price Target to $615 From $585, Maintains Buy Rating | MT |
| 09-23 | TD Cowen Adjusts PT on Vertex Pharmaceuticals to $550 From $525, Maintains Buy Rating | MT |
MarketScreener Strategies
Search
 | Vertex Pharmaceuticals Incorporated : Vertex and Crispr to market $2.2 million treatment for sickle cell disease | December 11, 2023 at 05:47 am |
 | Vertex Pharmaceuticals Incorporated : Confirms growth trajectory | May 04, 2023 at 09:35 am |
 | Vertex Pharmaceuticals : A very promising pipeline | January 11, 2023 at 05:20 am |
No results match your criteria
- Stock Market
- Stocks
- VRTX Stock
- News Vertex Pharmaceuticals Incorporated
- MarketScreener Strategies
Select your edition
All financial news and data tailored to specific country editions
